Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer

Seminars in Immunopathology

Volumn 39, Issue 3, 2017, Pages 245-253

  Watt, William C ^a,b   Cecil, Denise L ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b EpiThany Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOPHOSPHAMIDE; DACLIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; ETANERCEPT; FINGOLIMOD; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; RITUXIMAB; TRASTUZUMAB; VACCINE; AUTOANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BREAST CANCER; CANCER IMMUNOTHERAPY; COMPUTER MODEL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; INFLUENZA; MALIGNANT NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL; TUMOR IMMUNOLOGY; VACCINE IMMUNOGENICITY; ANIMAL; AUTOIMMUNE DISEASES; EPITOPE MAPPING; HELPER CELL; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH2 CELLS; VACCINES;

EID: 85006172771     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-016-0596-7     Document Type: Review

References (64)

1. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB et al (1994) Jan 1 Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54(1):16–20
2. Adler MJ, Dimitrov DS (2012) Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 26(3):447–481 vii
3. Aghajanian H, Cho YK, Manderfield LJ, Herling MR, Gupta M, Ho VC, Li L, Degenhardt K, Aharonov A, Tzahor E, Epstein JA (2016) Jun 30 Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor. Nat Commun 7:12038
4. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH (2015) Therapeutic cancer vaccines. J Clin Invest 125(9):3401–3412
5. Gjerstorff MF, Andersen MH, Ditzel HJ (2015) Jun 30 Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 6(18):15772–15787
6. Yang B, Jeang J, Yang A, Wu TC, Hung CF (2014) DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 10(11):3153–3164
7. Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) Mar 15 The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306
8. Bernard CC, de Rosbo NK (1991) Immunopathological recognition of autoantigens in multiple sclerosis. Acta Neurol (Napoli) 13(2):171–178
9. Rosenthal KS, Mikecz K, Steiner HL 3rd, Glant TT, Finnegan A, Carambula RE (2015) Zimmerman DH. Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Rev Vaccines 14(6):891–908
10. Reijonen H, Kwok WW, Nepom GT (2003) Detection of CD4+ autoreactive T cells in T1D using HLA class II tetramers. Ann N Y Acad Sci 1005:82–87
11. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) Aug 15 IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473–477
12. Behan PO, Chaudhuri A (2014) EAE is not a useful model for demyelinating disease. Mult Scler Relat Disord 3(5):565–574
13. Ben-Nun A, Kaushansky N, Kawakami N, Krishnamoorthy G, Berer K, Liblau R, Hohlfeld R, Wekerle H (2014) From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J Autoimmun 54:33–50
14. Rahma OE, Gammoh E, Simon RM, Khleif SN (2014) Sep 15 Is the “3 + 3” dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin Cancer Res 20(18):4758–4767
15. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM (2006) Jul 1 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19):3089–3094
16. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM (2015) Apr 20 Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33(12):1325–1333
17. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML (2015) Nov 21 Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386(10008):2078–2088
18. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology 17(6):854–861
19. Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG (2016) Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy 8(2):117–125
20. http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2168543
21. Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA (2012) Feb 10 Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med 10:28
22. Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE (2014) The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy 6(5):519–531
23. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N (2016) Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17(6):822–835
24. Wurz GT, Kao CJ, Wolf M, DeGregorio MW (2014) Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother 10(11):3383–3393
25. Goldman B, DeFrancesco L (2009) The cancer vaccine roller coaster. Nat Biotechnol 27(2):129–139
26. Qian F, Gnjatic S, Jäger E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood A, Old LJ, Odunsi K (2004) Nov 3 Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun 4:12
27. Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM (2002) Jan 1 NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62(1):213–218
28. Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM (2005) Feb 1 One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol 174(3):1751–1759
29. Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, Murphy R, Hoffman EW, Old LJ, Nakayama E, Iwatsuki K (2008) Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother 57(10):1429–1437
30. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P (2009) Mar 15 NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 15(6):2130–2139
31. Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W (2012) A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One 7(10):e48424
32. Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) May 1 Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines. J Immunol 162(9):5576–5583
33. Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65(8):794–802
34. Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60(3):433–442
35. Ribas A, Timmerman JM, Butterfield LH, Economou JS (2003) Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 24(2):58–61
36. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, Dela Rosa C, Tietje K, link J, Waisman J, Salazar LG (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27(28):4685–4692
37. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Jun 1 Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624–2632
38. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG (2015) Aug 15 Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res 21(16):3619–3630
39. Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG (2011) Feb 15 Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 71(4):1253–1262
40. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML (2003) Nov 15 Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9(15):5559–5565
41. Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C, Disis ML (2008) Oct 15 Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68(20):8400–8409
42. Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, Disis ML (2014) May 15 Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res 74(10):2710–2718
43. Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA (2013) Jul 15 TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19(14):3755–3763
44. Milich DR, McLachlan A, Raney AK, Houghten R, Thornton GB, Maruyama T, Hughes JL, Jones JE (1991) May 15 Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides. Proc Natl Acad Sci U S A 88(10):4348–4352
45. Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E, Kourilsky P (1992) Jan 1 Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A 89(1):416–420
46. Cabaniols JP, Cibotti R, Kourilsky P, Kosmatopoulos K, Kanellopoulos JM (1994) Dose-dependent T cell tolerance to an immunodominant self peptide. Eur J Immunol 24(8):1743–1749
47. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50(2):380–386
48. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62(2):120–126
49. Simon M, Girbal E, Sebbag M, Gomès-Daudrix V, Vincent C, Salama G, Serre G (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 92(3):1387–1393
50. Turunen S, Koivula MK, Melkko J, Alasaarela E, Lehenkari P, Risteli J (2013) Sep 23 Different amounts of protein-bound citrulline and homocitrulline in foot joint tissues of a patient with anti-citrullinated protein antibody positive erosive rheumatoid arthritis. J Transl Med 11:224
51. Gertel S, Serre G, Shoenfeld Y, Amital H (2015) Jun 15 Immune tolerance induction with multiepitope peptide derived from citrullinated autoantigens attenuates arthritis manifestations in adjuvant arthritis rats. J Immunol 194(12):5674–5680
52. Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, Pahau H, Lee BT, Ng J, Brunck ME, Hyde C, Trouw LA, Dudek NL, Purcell AW, O’Sullivan BJ, Connolly JE, Paul SK, Lê Cao KA, Thomas R (2015) Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med 7(290):290ra87
53. Yeste A, Takenaka MC, Mascanfroni ID, Nadeau M, Kenison JE, Patel B, Tukpah AM, Babon JA, DeNicola M, Kent SC, Pozo D, Quintana FJ (2016) Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2. Sci Signal 9(433):ra61
54. Streeter HB, Rigden R, Martin KF, Scolding NJ, Wraith DC (2015) Mar 12 Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS. Neurol Neuroimmunol Neuroinflamm 2(3):e93
55. Anderton SM, Viner NJ, Matharu P, Lowrey PA, Wraith DC (2002) Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat Immunol 3(2):175–181
56. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ (1999) Dec 21 Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci U S A 96(26):15050–15055
57. Burkhart C, Liu GY, Anderton SM, Metzler B, Wraith DC (1999) Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol 11(10):1625–1634
58. Gabrysová L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ, Wraith DC (2009) Aug 3 Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 206(8):1755–1767
59. Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H (2007) Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 64(10):1407–1415
60. Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F (2008) Steinman L; BHT-3009 study group. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 63(5):611–620
61. Liu R, Moise L, Tassone R, Gutierrez AH, Terry FE, Sangare K, Ardito MT, Martin WD, De Groot AS (2015) H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance. Hum Vaccin Immunother. 11(9):2241–2252
62. Cousens LP, Moise L, De Groot AS. Novel methods for addressing immunogenicity in therapeutic enzymes. In A. Rosenberg, B. Demeule (eds) Biobetters, AAPS Advances. American Association of Pharmaceutical Scientists 2015 in the Pharmaceutical Sciences Series 9
63. Losikoff PT, Mishra S, Terry F, Gutierrez A, Ardito MT, Fast L, Nevola M, Martin WD, Bailey-Kellogg C, De Groot AS, Gregory SH (2015) HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. J Hepatol 62(1):48–55
64. De Groot AS, Moise L, Liu R, Gutierrez AH, Tassone R, Bailey-Kellogg C, Martin W (2014) Immune camouflage: relevance to vaccines and human immunology. Hum Vaccin Immunother 10(12):3570–3575